SSAs such as Octreotide (Figure 1A) and Lanreotide (Figure 1D), which bind to somatostatin receptor 2 (SSTR2), and to a lesser extent, to SSTR5 and SSTR3, are effective in the treatment of secreting pituitary adenomas [11,12,13], but are poorly efficacious in NFPAs [14]. The gene discussed is SSTR2; the disease is pituitary gland adenoma.